Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 | 2 | GlobeNewswire (USA) | ||
14.05. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations | 106 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
08.05. | D.Boral Capital: Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference | 204 | Newsfile | Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May... ► Artikel lesen | |
07.05. | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
29.04. | Ernexa reports promising cancer cell therapy study results | 2 | Investing.com | ||
22.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
03.04. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Closes New Funding Round | 152 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced... ► Artikel lesen | |
ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
03.04. | Eterna Therapeutics Inc. - 8-K, Current Report | 5 | SEC Filings | ||
25.03. | Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease | 113 | GlobeNewswire (Europe) | Ernexa Therapeutics embarks on new strategic direction, shifting the company's focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company's... ► Artikel lesen | |
24.03. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.03. | Eterna Therapeutics Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
12.03. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
26.02. | Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline | 6 | GlobeNewswire (USA) | ||
13.02. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
28.01. | Eterna Therapeutics expands scientific board with oncology experts | - | Investing.com | ||
28.01. | Eterna Therapeutics erweitert wissenschaftlichen Beirat mit Onkologie-Experten | 8 | Investing.com Deutsch | ||
28.01. | Eterna Therapeutics Announces Expansion of Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
14.01. | Eterna Therapeutics reports breakthrough in ovarian cancer treatment | 4 | Investing.com | ||
14.01. | Eterna Therapeutics meldet Durchbruch bei der Behandlung von Eierstockkrebs | 13 | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,088 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,410 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,570 | -100,00 % | VivoSim Labs, INC. - 10-K, Annual Report | ||
OCUGEN | 0,917 | +9,98 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,050 | 0,00 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,530 | +6,85 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
VAXART | 0,364 | +5,63 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders | ||
BURCON NUTRASCIENCE | 0,072 | -1,10 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 0,330 | -6,25 % | Cellectar +147%: Ich nehme die Gewinne mit! | Meine Spekulation geht auf: Cellectar Biosciences (WKN: A3DQSD) knallt heute in der Spitze um bis zu +147% durch die Decke, nachdem ich im März ein großes Comeback der Aktie in Aussicht gestellt hatte.... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
IMMUNIC | 0,704 | +5,23 % | Immunic sammelt 65 Millionen Dollar ein - Aktie reagiert | Immunic meldet für die erste Tranche einer Kapitalmaßnahme einen Bruttoerlös von rund 65 Millionen Dollar. Das Biotech-Unternehmen platzierte im Rahmen eines öffentlichen Angebots vorfinanzierte Aktien-Warrants... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,106 | +0,95 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
CEL-SCI | 2,360 | 0,00 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |